BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical Key Statistics
Pro Data ExportCurrent Valuation
Dividends and Shares
| Dividend | |
| Dividend Yield | 0.00% |
| Cash Div. Payout Ratio TTM Pro | Go Pro |
| Payout Ratio TTM Pro | Go Pro |
| Dividend Date | |
| Ex-Dividend Date | |
| Last Split Factor | |
| Last Split Date |
Profitability
| Gross Profit Margin | 85.34% |
| EBITDA Margin TTM Pro | Go Pro |
| Operating Margin TTM Pro | Go Pro |
| Profit Margin | -20.55% |
Management Effectiveness
Liquidity and Solvency
| Altman Z-Score Pro | Go Pro |
| Current Ratio | 4.285 |
| Debt to Equity Ratio | 0.4512 |
| KZ Index Pro | Go Pro |
| Tangible Common Equity Ratio Pro | Go Pro |
| Times Interest Earned TTM Pro | Go Pro |
Stock Price Performance
| Beta Pro | Go Pro |
| 1 Month Stock Returns | 10.21% |
| Year to Date Stock Returns | 12.39% |
| 1 Year Stock Returns | 38.15% |
| 3 Year Stock Returns | 174.6% |
| 52 Week High | 39.20 |
| 52 Week Low | 23.74 |
Income Statement
| Revenues TTM | 448.55M |
| Revenue Per Share TTM | 3.880 |
| Revenue Growth | 6.57% |
| Gross Profit TTM | 368.22M |
| EBITDA TTM Pro | Go Pro |
| Income from Cont. Ops Pro | Go Pro |
| Net Income TTM | -73.44M |
| Earnings Per Share TTM | -0.65 |
| Other Comprehensive Income Pro | Go Pro |
Cash Flow Statement
| Cash Investing TTM | -62.49M |
| Cash Financing TTM | 39.21M |
| Cash Operations TTM | 15.08M |
| Capital Expenditures | 6.179M |
Share Statistics
| Shares Outstanding | 115.62M |
Balance Sheet
| Cash and ST Investments | 232.98M |
| Total Assets | 1.297B |
| Liabilities | 525.14M |
| Book Value | 771.95M |
| Book Value per Share | 6.677 |
| Tangible Book Value Pro | Go Pro |
| Tangible Book Value Per Share Pro | Go Pro |
| Long Term Debt | 348.33M |
Earnings Quality
| Accruals Pro | Go Pro |
| Beneish M-Score Pro | Go Pro |
You may also be interested in these BMRN related companies
BMRN News
RT @TheEquitiesRoom: Stocks trading down to 20d support: $EIX $DRI $SWI $BMC $OPTR $BMRN $HSY < nice list
about 7 days ago by 1nvestor
about 7 days ago by 1nvestor
Five Stocks Hit 52-Week Highs $RDWR $CHDN $LL $BMRN $MTH http://stks.co/3rG6 My story via @TheStreet
about 12 days ago by azendrian
about 12 days ago by azendrian
$BMRN Insider Sale: $1.5M of stock sold by Bienaime Jean Jacques between May 11, 2012 - May 14, 2012 http://stks.co/3qP6
about 12 days ago by MarketBrief
about 12 days ago by MarketBrief
$BMRN Insider Sale: $1.6M of stock sold by Davis George Eric on May 11, 2012 http://stks.co/3qOj
about 12 days ago by MarketBrief
about 12 days ago by MarketBrief
Listen to $BMRN inc. at deutsche bank ag health care conference - live at 08:00 AM, ondemand after - http://stks.co/3jp6
about 19 days ago by earningscast
about 19 days ago by earningscast
BioMarin Appoints Dan Spiegelman as Executive Vice President and Chief Financial Officer
May 08, 4:05PM Benzinga
May 08, 4:05PM Benzinga
$BMRN Insider Sale: $1.1M of stock sold by Bienaime Jean Jacques between May 1, 2012 - May 2, 2012 http://stks.co/3elV
about 25 days ago by MarketBrief
about 25 days ago by MarketBrief
BioMarin Pharmaceutical's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Apr 27, 3:10AM Seeking Alpha
Apr 27, 3:10AM Seeking Alpha
Listen to $BMRN Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3XW8
about 31 days ago by earningscast
about 31 days ago by earningscast
BioMarin Pharma (BMRN) Misses Q1 EPS by 7c; Raises FY12 Sales Guidance
Apr 26, 4:50PM Street Insider
Apr 26, 4:50PM Street Insider
$BMRN http://stks.co/3Njb $BMRN, Buy at trendline & 200 day ma support. Robust pipeline
about 41 days ago by Catalystrader
about 41 days ago by Catalystrader
UPDATE - UBS Initiates Coverage on BioMarin (BMRN) with a Buy; Accumulate on Pullback
Apr 12, 11:07AM Street Insider
Apr 12, 11:07AM Street Insider
$BMRN http://stks.co/3IgM Weekly triangle break down. Worth watch for new setup after new up correction http://stks.co/3IgN
about 47 days ago by xpertstocktrader
about 47 days ago by xpertstocktrader
$BMRN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3DE1
about 54 days ago by MarketBrief
about 54 days ago by MarketBrief
$BMRN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3C5Q
about 55 days ago by MarketBrief
about 55 days ago by MarketBrief
$BMRN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3Amr
about 56 days ago by MarketBrief
about 56 days ago by MarketBrief
BioMarin Completes Enrollment for Phase 3 Trial for GALNS for the Treatment of MPS IVA
Mar 08, 9:02AM Benzinga
Mar 08, 9:02AM Benzinga
BioMarin (BMRN) Announces Completion of Enrollment for Phase 3 Study on GALNS
Mar 08, 9:02AM Street Insider
Mar 08, 9:02AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BMRN | 38.64 | +0.13 | +0.34% | 4.468B |
| BMR | 18.25 | -0.17 | -0.92% | 2.815B |
| BMO | 52.99 | -0.73 | -1.36% | 33.94B |
| BMJ | 0.93 | +0.00 | +0.00% | |
| BLC | 5.85 | -0.03 | -0.51% | 608.52M |
| BKYF | 23.80 | -0.23 | -0.96% | 177.31M |
| BKT | 7.52 | +0.00 | +0.00% | |
| BKSC | 11.64 | +0.19 | +1.66% | 51.80M |
| BKS | 17.23 | +0.19 | +1.11% | 1.037B |
| BKR | 22.63 | +0.01 | +0.04% | 215.89M |
